Zacks: Brokerages Expect BioCardia, Inc. (NASDAQ:BCDA) Will Post Quarterly Sales of $190,000.00

Wall Street brokerages forecast that BioCardia, Inc. (NASDAQ:BCDAGet Rating) will report sales of $190,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for BioCardia’s earnings, with the lowest sales estimate coming in at $130,000.00 and the highest estimate coming in at $250,000.00. BioCardia reported sales of $50,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 280%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that BioCardia will report full-year sales of $750,000.00 for the current fiscal year, with estimates ranging from $500,000.00 to $1.00 million. For the next fiscal year, analysts expect that the firm will report sales of $630,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for BioCardia.

BioCardia (NASDAQ:BCDAGet Rating) last posted its earnings results on Tuesday, March 29th. The company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.01. BioCardia had a negative return on equity of 87.02% and a negative net margin of 1,243.65%. During the same quarter last year, the firm earned ($0.16) EPS.

Several analysts have issued reports on BCDA shares. Zacks Investment Research raised BioCardia from a “sell” rating to a “hold” rating in a research note on Monday, April 11th. Brookline Capital Management reissued a “buy” rating on shares of BioCardia in a research note on Thursday, February 3rd.

BCDA stock opened at $1.59 on Friday. The business’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $2.16. BioCardia has a 1-year low of $1.25 and a 1-year high of $5.10. The firm has a market cap of $26.82 million, a PE ratio of -2.12 and a beta of 1.32.

Several large investors have recently added to or reduced their stakes in BCDA. Virtu Financial LLC acquired a new stake in shares of BioCardia in the fourth quarter valued at about $109,000. Commonwealth Equity Services LLC increased its position in shares of BioCardia by 156.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 42,307 shares of the company’s stock valued at $82,000 after acquiring an additional 25,815 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of BioCardia in the third quarter valued at about $31,000. 14.86% of the stock is currently owned by institutional investors and hedge funds.

About BioCardia (Get Rating)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease.

See Also

Get a free copy of the Zacks research report on BioCardia (BCDA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with's FREE daily email newsletter.